Adjuvant chemotherapy for node-positive breast cancer: A retrospective comparison of two different regimens of cyclophosphamide, methotrexate and 5-fluorouracil

Breast

Volumn 8, Issue 1, 1999, Pages 28-34

  Yip, D ^a   Rangan, A M ^a   Harnett, P R ^a   Ahern, V ^a   Boyages, J ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b NSW Breast Cancer Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; AMENORRHEA; ARTICLE; AXILLARY LYMPH NODE; BOLUS INJECTION; BREAST CANCER; CANCER SURVIVAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

EID: 0032910036     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(99)90335-1     Document Type: Article

References (26)

1. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
2. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-410.
3. Ragaz J, Jackson S M, Le N et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-962.
4. DeVita V T, Serpick A, Carbone P P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73: 891-895.
5. Bonadonna G, Valagussa P, Tancini G et al. Current status of the Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1986; 1: 45-49.
6. Dombernowsky P, Brincker H, Hansen M et al. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Acta Oncol 1988; 27: 691-697.
7. Mauriac L, Durand M, Chauvergne J et al. Adjuvant trial for stage II receptor-positive breast cancer. CMF versus CMF plus tamoxifen in a single centre. Breast Cancer Res Treat 1988; 11: 179-186.
8. Lindeman G J, Boyages J, Driessen C, Langlands A O. Intravenous or oral adjuvant CMF for node-positive breast cancer. Aust NZ J Surg 1992; 62: 556-562.
9. Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983; 1: 2-10.
10. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-15.
11. Green J, Dawson A, Fell L. Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol 1980; 9: 511-514.
12. WHO. Handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva, WHO, 1979.
13. Gelman R, Gelber R, Henderson I C, Coleman C N, Harris J R. Improved methodology for analyzing local and distant recurrence. J Clin Oncol 1990; 8: 548-555.
14. Hryniuk W, Levine L. Dose intensity for adjuvant chemotherapy trials in Stage II breast cancer. J Clin Oncol 1986; 6: 1162-1170.
15. Wood W, Budman D, Korzun A et al. Dose and dose intensity of adjuvant chemotherapy for stage II node positive breast carcinoma. N Engl J Med 1994; 330: 1253-1259.
16. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 15: 1885-1894.
17. Marini G, Murray A, Goldhirsch A et al. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. Ann Oncol 1996; 7: 245-250.
18. Rossi A, Bonadonna G, Valagussa P, Veronesi V. Multimodal treatment in operable breast cancer: five year results of the CMF programme. BMJ 1981; 282: 1427-1431.
19. Brandi M, DeMitrio A, Doitonno P et al. Oral versus intravenous CMF in metastatic breast cancer: a randomised study. Int J Oncol 1994; 4: 559-565.
20. Engelsman E, Klijn J C M, Rubens R D et al. 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 1991; 27: 966-970.
21. Goldhirsch A, Coates A S, Colleoni M, Castiglione-Gertsch M, Gelber R D. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. J Clin Oncol 1998; 16: 1358-1362.
22. Bagley C M, Bosllick F W, DeVita V T. Clinical pharmacology of cyclophosphamide. Cancer Res 1973; 33: 226-233.
23. Gheuens E, Slee P H, De Bruijn E A. Bioavailability of cyclophosphamide in the CMF regimen. Onkologie 1990; 13: 203-206.
24. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-2611.
25. Lindley C, Vasa S, Sawyer W T, Winer E P. Quality of life and preference for treatment following systemic adjuvant therapy for early stage breast cancer. J Clin Oncol 1998; 16: 1380-1387.
26. Ravdin P M, Siminott L A, Harvey J A. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998; 16: 515-521.